Iatrogenicity

TABLE OF CONTENTS

Part I: MEDICAL HARM

1.      The Concept and Spectrum of "Iatrogenicity"

I. Gussak and J. Kostis

2.      Iatrogenicity:  Definition, History and Modern Context

M. Gussak, I. Gussak, and J. Kostis

3.      Epidemiology and Public Health Aspects and Implications:  Regulatory, Legal and Ethical Dimensions of Iatrogenicity

S. Jones and M. Gonzalez

4.      Risk Management:  The Medical Center Administration Perspective

S. Jones and M. Gonzalez

5.      Iatrogenicity from the Patient's Perspective

J. Dobrzynski, S. Jones, and M. Gonzalez

6.      A Naturopathic Perspective on Iatrogenesis

C. Fleetwood

Part II:  IATROGENICITY OF CARDIOVASCULAR DURGS AND CARDIOVASCULAR TOXICITY OF NON-CARDIAC DRUGS

7.      Clinical Manifestations of Acute and Chronic Drug-Induced Iatrogenic Cardiovascular Diseases and Syndromes

I. Gussak, G. Yan, A. Jahangir, and J. Kostis

8.      Drug-Induced Cardiac Arrhythmias and Sudden Cardiac Death

A. Narichania, Y. Yokoyama, and W.K. Shen

9.      Chemotherapy-Induced Cardiomyopathies

E. Birati and B. Jessup

10.  Iatrogenicity of Blood Pressure Mesaurement in the Diagnosis of Hypertension

T. Giles, G. Sander, I. Gussak, and J. Kostis

11.  Antihypertensive Drug-Induced Iatrogenic Cardiovascular Syndromes

R. Kalaitzidis and G. Bakris

12.  Iatrogenicity of Cardiovascular Drugs Associated with Cardiac and Non-Cardiac Toxicities: Antihypertensive Agents and Biologics

E. Hermes-Desantis and J. Barone

13.  Iatrogenic Aspects of Hypertension in Pregnancy: Focus on Preeclampsia

C. Thomopoulos and T. Makris

14.  Women and Iatrogenic Cardiovascular Disease:  Menopausal Estrogen as the Prime Suspect

G. Bachmann, M. Rees, and N. Phillips

15.  Iatrogenic Aspects of Lipid-Lowering Agents, Thrombolytic, Antiplatelet, and Antithrombotic Agents

C. Tsioufis, D. Konstantinidis, N. Vogiatzakis, and K. Dimitriadis

16.  Iatrogenic Effects of ‘Urologic' Drugs on the Cardiovascular System

K. Stavropoulos, C. Boutari, K. Imprialos, and M. Doumas

17.  Iatrogencity and Antianginal Drugs

A. Moreyra and W.J. Kostis

18.  Anti-Diabetic Drugs and Cardiovascular Risk: Where Do We Stand?

R. Kumar

19.  Cardiovascular Iatrogenicity in Older Adults

A. Khan, #. Ali, #. Iyengar, #. Hagiwara, #. Periyakoil, #. Patel, #. Malone

Part III:  IATROGENCITY OF DIAGNOSTIC AND THERAPEUTIC, INVASIVE AND NON-INVASIVE CARDIOVASCULAR INTERVENTION, DEVICES, AND SURGERIES

20.  Iatrogenic Aspects of Non-Invasive and Invasive Diagnostic Methods in Interventional Cardiology

C. DÖsch, D. Loßnitzer, T. Papavassiliu

21.  Iatrogenicity Associated with Interventional Treatment Modalities

N.V. Pothineni, A. Garg, H. Paydak, and J.L. Mehta

22.  Iatrogenicity of Diagnostic and Therapeutic, Invasive and Non-Invasive Cardiovascular Interventions, Devices and Surgeries

M. Behnes, T. Becher, S. Baumann, and I. Akin

23.  Iatrogenic Aspects in Cardiac Electrophysiology

B. Rudic, E. TÜlÜmen, and V. Liebe

24.  Iatrogenic Aspects in Cardiac Device Therapy

S. RÖger and J. Kuschyk

25.  Cardiovascular Iatrogencity of Respiratory Therapeutic Modalities

M.S. Nolledo, P. Lerma and T.V. Santiago

Part IV:  IATROGENIC ASPECTS OF SPORT CARDIOLOGY AND LIFE-STYLE MODIFICATIONS

26.  Professional Athletes

G. Mancia

27.  Sports Cardiology

G. Campanile

28.  Dangers of Lifestyle Modification Advice

G. Campanile

Part V:  IATROGENICITY OF DIETARY SUPPLEMENTS, HERBAL PRODUCTS, AND OTHER NON-TRADITIONAL THERAPIES IN CARDIOVASCULAR MEDICINE

29.  Safety of Over-the-Counter ‘Natural Substances’ and Vitamins:  Side-effects and Contraindications

S. Sultan, A. Jahangir, C. Ding, H. Cao, J.B. Kostis, I.B. Gussak, and A. Jahangir

30.  Interactions Between Supplements and Prescription Medications

S. Sultan, A. Jahangir, C. Ding, H. Cao, J.B. Kostis, I.B. Gussak, and A. Jahangir

Acknowledgments

Index